Oncology (all articles) | Page 75 of 122 | Links Medicus Content Curation & Alerts in Medicine

Routine testing for bowel cancer should not be recommended for everyone aged 50-79 years because, for those at very low risk, the benefit is small and uncertain and there are potential harms, finds new #RapidRecs guideline https://t.co/68xTtEDHxQ

— The BMJ (@bmj_latest) October 3, 2019

[Abstract Only] Cohort Study: Factors Associated with Breast Cancer–related Lymphedema after Neoadjuvant Chemotherapy and Axillary Dissection

2 Oct, 2019 | 01:35h | UTC

Factors Associated with Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection – JAMA Surgery (link to abstract – $ for full-text)

Commentaries: Neoadjuvant Chemotherapy Duration and Obesity May Be Associated With Increased Risk of Lymphedema in Some Women With Breast Cancer – The ASCO Post (free) AND Lymphedema Risk in Breast Ca Linked to NAC Duration – MedPage Today (free registration required)

FDA Issues Drug Safety Alert on Severe Lung Inflammation Due to Treatment with CDK4/6 Inhibitors for Breast Cancer

1 Oct, 2019 | 00:36h | UTC

FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer – U.S. Food & Drug Administration (free)

Commentary: FDA Issues Drug Safety Communication on Lung Inflammation Due to Treatment With CDK4/6 Inhibitors – The ASCO Post (free)

Global Burden of Cancer, 1990 to 2017

30 Sep, 2019 | 00:42h | UTC

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study – JAMA Oncology (free)

Related Commentary on Twitter

To ensure sustainable global development, increased efforts are needed in cancer prevention and in ensuring universal access to cancer care. https://t.co/6HDaU8Ped9

— JAMA Oncology (@JAMAOnc) September 27, 2019

#ESMO19 – Randomized Trial: Improved Overall Survival with a CDK4/6 Inhibitor for Hormone Receptor-positive, ERBB2-negative Advanced Breast Cancer

30 Sep, 2019 | 00:40h | UTC

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial – JAMA Oncology (free)

Commentary: Two Studies Show CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer [ESMO 2019 Press Release] (free)

#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona

#ESMO19 – [Not Published Yet] Randomized Trial: Many Men with Prostate Cancer May Avoid Postoperative Radiotherapy, Study Suggests

30 Sep, 2019 | 00:39h | UTC

Men with Prostate Cancer can be Spared Radiotherapy after Surgery [ESMO 2019 Press Release] (free)

#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona

#ESMO19 – [Abstract Only] Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

30 Sep, 2019 | 00:37h | UTC

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Skin cancer: Half of people surviving advanced melanoma – BBC (free) AND Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates – The Royal Marsden NHS Foundation Trust (free)

#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona

Related Commentary on Twitter

With a 5-year min follow-up, the combination of nivolumab plus ipilimumab associated with 5-year survival of 52% in patients with metastatic #melanoma, compared with 44% for nivolumab alone and 26% for ipilimumab alone. See the CheckMate 067 trial. #ESMO19 https://t.co/f50KNzH5tp

— NEJM (@NEJM) September 28, 2019

Stay Updated in Your Specialty